fda semaglutide compounding news moves to stop GLP-1 drugs Compounded Semaglutide Manufacturing Ban

As new medications receive approval, youll have more options to consider

The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics

Tirzepatide availability changes and why vendors are pulling it The tirzepatide market for research peptides has undergone seismic shifts

In This Review Overview Everyone wants to get in shape, but not everyone can afford expensive GLP-1 shots that are so popular these days

The emergence of the gut-heart axis concept might imply a potential connection between the gut microbiota and myocarditis